Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer

Lancet. 2023 Dec 9;402(10418):2168-2170. doi: 10.1016/S0140-6736(23)02296-1. Epub 2023 Oct 20.

Authors

Elizabeth C Smyth¹, Raghav Sundar²

Affiliations

¹ Oxford National Institute for Health and Care Research Biomedical Research Centre, Churchill Hospital, Oxford OX3 7LE, UK. Electronic address: elizabeth.smyth2@nhs.net.
² Department of Haematology-Oncology, National University Cancer Institute, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

PMID: 37871605
DOI: 10.1016/S0140-6736(23)02296-1

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Esophageal Neoplasms* / drug therapy
Humans
Immune Checkpoint Inhibitors / therapeutic use
Receptor, ErbB-2
Stomach Neoplasms* / drug therapy
Trastuzumab / therapeutic use

Substances

Trastuzumab
Immune Checkpoint Inhibitors
Receptor, ErbB-2